[{"id":"a23f5d63-8e69-4dcb-9f4a-d25c6f0b4637","acronym":"GAMY","url":"https://clinicaltrials.gov/study/NCT06559033","created_at":"2025-02-26T10:08:15.274Z","updated_at":"2025-02-26T10:08:15.274Z","phase":"","brief_title":"Determine the Frequency of Variants in the GBA/PSAP Genes in Patients with MM or MGUS","source_id_and_acronym":"NCT06559033 - GAMY","lead_sponsor":"University Hospital, Rouen","biomarkers":" PSAP","pipe":"","alterations":" ","tags":["PSAP"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 10/02/2026","primary_completion_date":" 10/02/2026","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-12-09"},{"id":"97e655f1-4ba9-4ef3-8071-5589520a47b8","acronym":"NCI-2014-00318","url":"https://clinicaltrials.gov/study/NCT01804465","created_at":"2021-01-18T07:59:42.271Z","updated_at":"2025-02-25T14:34:03.803Z","phase":"Phase 2","brief_title":"Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer","source_id_and_acronym":"NCT01804465 - NCI-2014-00318","lead_sponsor":"University of California, San Francisco","biomarkers":" PSAP","pipe":"","alterations":" ","tags":["PSAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • Provenge (sipuleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 04/22/2014","start_date":" 04/22/2014","primary_txt":" Primary completion: 02/27/2020","primary_completion_date":" 02/27/2020","study_txt":" Completion: 08/31/2020","study_completion_date":" 08/31/2020","last_update_posted":"2021-08-18"},{"id":"be0663b5-2478-4403-8fcb-c2a5b443dd4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01881867","created_at":"2021-01-18T08:26:13.034Z","updated_at":"2024-07-02T16:36:58.281Z","phase":"Phase 2","brief_title":"CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT01881867","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" IFNG • CSF2 • PSAP","pipe":"","alterations":" ","tags":["IFNG • CSF2 • PSAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CYT107"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 09/10/2013","start_date":" 09/10/2013","primary_txt":" Primary completion: 05/15/2017","primary_completion_date":" 05/15/2017","study_txt":" Completion: 01/02/2018","study_completion_date":" 01/02/2018","last_update_posted":"2019-07-09"},{"id":"191da7f5-edb6-463a-a59a-a983b6c6378f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01832870","created_at":"2021-01-18T08:09:16.755Z","updated_at":"2024-07-02T16:37:18.514Z","phase":"Phase 1","brief_title":"Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer","source_id_and_acronym":"NCT01832870","lead_sponsor":"Prostate Oncology Specialists, Inc.","biomarkers":" PSAP","pipe":"","alterations":" ","tags":["PSAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • Provenge (sipuleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 02/01/2016","primary_completion_date":" 02/01/2016","study_txt":" Completion: 02/01/2016","study_completion_date":" 02/01/2016","last_update_posted":"2017-08-24"}]